Menu

Report Library

All Reports

Biomedtracker Q3 2018 Outlook Report

July 05, 2018

In this report, we cover catalysts from 23 drugs expected to occur in Q3 2018. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. The results of the catalysts highlighted in our Q2 2018 Outlook Report can be found on Page 4. At the end of this report, we have included a list of Large Impact catalysts through Q3 2018.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst list is provided in Excel by downloading the supplemental material at the top of this page.

Interested in medical devices? Our sister product Meddevicetracker has published a concurrent report on 10 device catalysts expected to occur in Q3 2018. This report can be downloaded for free here.


Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.

For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: Acute Myelogenous Leukemia (AML)
Crohn's Disease
Cutaneous T-Cell Lymphoma (CTCL) - NHL
Diffuse Large B-Cell Lymphoma (DLBCL) - NHL
End-Stage Renal Disease (ESRD)
Endometriosis
Fabry's Disease
Food Allergies
Hereditary Angioedema (HAE)
Hyperinsulinemia/Hypoglycemia
Intra-Abdominal Infections (Antibacterial)
Leber's Hereditary Optic Neuropathy (LHON) (Ophthalmology)
Liver Failure / Cirrhosis
Migraine and Other Headaches
Neuroendocrine Tumors (NET)
Non-Small Cell Lung Cancer (NSCLC)
Post-Traumatic Stress Disorder (PTSD)
Respiratory Tract Infections (Excluding Pneumonia)
Smallpox
Thrombocytopenia
Uterine Fibroids
Uveitis (Ophthalmology)

 Additional Resources: